Chronic Respiratory Diseases as a Risk Factor for Herpes Zoster Infection

Morena, Diego; Lumbreras, Sara; Rodríguez, José Miguel; Campos, Carolina; Castillo, María; Benavent, María; Izquierdo, José Luis

doi:10.1016/j.arbres.2023.08.010

Cited by 6 publications

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to a study using German claims data, patients with asthma, coronary heart disease, chronic obstructive pulmonary disease (COPD), depression, and rheumatoid arthritis had an average of 30% increased risk of developing acute herpes zoster compared with patients without any chronic underlying conditions [ 30 ]. In a recent large population analysis using artificial intelligence, COPD, asthma, and lung cancer demonstrated a higher risk of developing herpes zoster [ 28 ] ( Table 1 ). Regarding postherpetic neuralgia, an increased risk was only observed in patients with COPD (odd ratio (OR) 1.24 [95% CI 1.23–1.25]) and lung cancer (1.14 [1.13–1.16]).…”

Section: Risk Factors For Herpes Zostermentioning

confidence: 99%

Herpes Zoster and Cardiovascular Disease: Exploring Associations and Preventive Measures through Vaccination

Yamaoka-Tojo,

Tojo

2024

Vaccines

View full text Add to dashboard Cite

Herpes zoster, induced by the reactivation of the varicella-zoster virus (VZV), is a unilaterally distributed vesicular rash that can cause multiple complications. VZV not only causes neurological problems, including postherpetic neuralgia and ocular zoster, but also causes inflammatory vasculopathy and increases the incidence of hemorrhagic or ischemic complications. Therefore, understanding the association between the development of herpes zoster and the subsequent occurrence of acute stroke or cardiovascular diseases, including myocardial infarction and heart failure, is of great interest. Conversely, many risk factors are involved in the development of herpes zoster. Recently, it has become clear that aging, insufficient immune function, and diseases related to lifestyle habits (for example, stroke and cardiovascular disease), can trigger the onset of herpes zoster. Preventing the onset of herpes zoster, which substantially reduces quality of life, will lead to lower medical costs for countries and extend healthy life expectancy for general populations. Thus, because herpes zoster is a vaccine-preventable disease, active vaccination is recommended for high-risk groups. This review summarizes the association between herpes zoster and cardiovascular disease and vaccination against herpes zoster as a useful disease management and prevention measure for cardiovascular disease.

show abstract

Section: Risk Factors For Herpes Zostermentioning

confidence: 99%

Herpes Zoster and Cardiovascular Disease: Exploring Associations and Preventive Measures through Vaccination

Yamaoka-Tojo,

Tojo

2024

Vaccines

View full text Add to dashboard Cite

show abstract

The effect of recombinant zoster vaccine on patients with chronic obstructive pulmonary diseases: A multi‐institutional propensity score‐matched cohort study

Tsai,

Zhang,

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

Although the recombinant zoster vaccine (RZV) has demonstrated efficacy in reducing the risk of herpes zoster (HZ) for individuals aged 50 years and older, its effectiveness in patients with chronic obstructive pulmonary disease (COPD) remains uncertain. This study was conducted to assess the effect of RZV on the risk of HZ in COPD patients. A multi‐institutional propensity score‐matched retrospective cohort study was conducted using the TriNetX Research network, including individuals aged 40 years or older with COPD from January 1, 2018, to December 31, 2022. Patients with a history of HZ or prior zoster vaccination were excluded. The primary outcome was HZ occurrence, with secondary outcomes including severe and nonsevere HZ. After propensity score matching, each 17 431 patients receiving RZV and unvaccinated patients were included. The vaccinated group had a significantly lower risk of HZ compared to the unvaccinated group (HR, 0.62; [95% confidence intervals] 95% CI, 0.51–0.75, p < 0.01). Similar risk reductions were observed for nonsevere HZ (HR, 0.61; 95% CI, 049–0.75, p < 0.01) and severe HZ (HR, 0.53; 95% CI, 0.38–0.73, p < 0.01). Further subgroup analyses demonstrated consistent risk reductions across age (50–59, 60–69, 70–79, and ≥80 years), sex, and comorbidities, except for individual aged 40–49 years. This study confirms the effectiveness of RZV in reducing HZ risk in patients with COPD aged 50 years and older, supporting its administration in this population. However, vaccination rates remain low, highlighting the need for improved vaccination strategies in this high‐risk group. Efforts to enhance vaccine uptake are warranted to reduce HZ morbidity.

show abstract

National trends and disparities in herpes zoster vaccination among U.S. older adults with chronic obstructive pulmonary disease, 2008-2022

Hung,

Wang,

Suk

2024

American Journal of Infection Control

View full text Add to dashboard Cite

Chronic Respiratory Diseases as a Risk Factor for Herpes Zoster Infection

Cited by 6 publications

References 36 publications

Herpes Zoster and Cardiovascular Disease: Exploring Associations and Preventive Measures through Vaccination

Herpes Zoster and Cardiovascular Disease: Exploring Associations and Preventive Measures through Vaccination

The effect of recombinant zoster vaccine on patients with chronic obstructive pulmonary diseases: A multi‐institutional propensity score‐matched cohort study

National trends and disparities in herpes zoster vaccination among U.S. older adults with chronic obstructive pulmonary disease, 2008-2022

Contact Info

Product

Resources

About